Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.» Read More
Analysts say Gustav’s punishing blow to the Louisiana coastline Monday will cost nowhere near as much as Katrina three years ago, the New York Times reports..
If you're not covered, this is what you need to do now.
After the closing bell Monday, Eli Lilly and Amylin Pharmaceuticals announced that they're going to hold a conference call for analysts and investors about their diabetes drug Byetta. Why?
As we head into my last free summer weekend before USC's football season kicks off, I wanted to clean out the Pharma's Market mailbox. (Actually I was looking for an apropos-of-nothing excuse to mention the Trojans.)
The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.
Flying isn't the only rip-off. Your whole vacation is littered with hidden fees and surcharges, but you don't have to pay them all.
Before I get to my favorite biotech saga, there are noteworthy, if not newsworthy, press releases out this morning from two takeout targets. Genentech put out a statement from the special independent board committee that's been appointed to handle the Roche buyout offer.
European financial groups ING and Zurich Financial Services reported quarterly profits that met or exceeded expectations on Wednesday, helped by strong insurance businesses and limited investment writedowns.
American International Group, the world's largest insurer, may have to raise more capital to bolster its balance sheet if its credit ratings are cut again, Goldman Sachs analyst Tom Cholnoky said in a note to clients.
AIG reports weak earnings and further write-downs, while GE says the Beijing Olympics will help boost the company's brand image. Following are today's top videos:
Stocks ended near session lows as oil ended above $120 a barrel and two Dow components missed the Street's targets.
Stocks pared some losses Thursday afternoon as oil prices flattened out. Putting pressure on stocks today was a quartet of dismal news: a rise in jobless claims, oil's resurgence, Wal-Mart's sales miss and AIG's wider-than-expected loss.
AXA Europe's second-biggest insurer, reported lower first-half net profit on Thursday although the earnings came in above the average market forecast and AXA said it needed no capital increase.
Stocks opened lower, clipped by a quartet of dismal news: a rise in jobless claims, oil's resurgence, Wal-Mart's sales miss and AIG's wider-than-expected loss. But a better-than-expected report on home sales helped shave a few points off the decline.
Stock futures fell further after a report showed jobless claims unexpectedly rose last week. Futures had already been pointing lower as oil rose nearly $3 a barrel, Wal-Mart missed sales estimates and Dow component AIG posted a wider-than-expected loss.
Europe's biggest insurer Allianz abandoned its profit targets and said on Wednesday new guidance was impossible given financial market turmoil that kept its Dresdner Bank firmly in the red in the second quarter.
American International Group reported a quarterly loss of 51 cents a share, falling far short of analysts' estimates, which had projected a profit for the company.
Bond insurer Ambac Financial reported sharply higher quarterly net income on Wednesday on valuation gains on some securities, sending its shares up more than 12 percent in early trading.
Health insurer Humana posted quarterly profit that beat estimates and lifted its 2008 forecast on Monday on better-than-expected results for its Medicare prescription drug plans for seniors, sending shares more than 4 percent higher.
Health insurer Cigna posted better-than-expected quarterly profit Friday, helped by its Great West acquisition and operating expense controls, but cut the outlook for its main health-care segment.
Get the best of CNBC in your inbox